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Translational research to discover ther-
apeutic targets for stroke has not fared
well in developing new treatments for
patients. The three most pressing issues
are the choice of therapeutic target, animal
model, and timepoint of administration
of treatment. This manuscript “Different
immunological mechanisms govern pro-
tection from experimental stroke in young
and older mice with recombinant TCR lig-
and therapy” provides a fresh approach
toward developing stroke treatments
(Offner et al., 2014). This study examines
treating with recombinant TCR ligand
(RTL) in both young and older mice 4
hours after MCAO. RTL consist of the
specific domains of MHC II molecule
and inhibits activation of T cells toward
inflammation. The novelties of this study
are several fold including: (1) inhibition of
a specific immunoinflammatory pathway
to avoid total immunosuppression, (2) use
of elderly mice to mimic the population of
human patients and (3) administration at
a clinically relevant timepoint.
For a number of years, researchers have
reported the entry of immune cells into
the area of the infarct, which leads to fur-
ther neurodegeneration. However, target-
ing this immune response as a treatment
for stroke remains elusive (Iadecola and
Anrather, 2011). In the past several years,
the spleen has been reported to be a focal
point for the immune system to mount
an inflammatory response that exacer-
bates stroke-induced neurodegeneration
(Offner et al., 2006; Vendrame et al., 2006).
In fact, ablation of the spleen reduces
inflammation and neural cell death in
the rodent brain after experimental stroke
(Ajmo et al., 2008; Ostrowski et al., 2012;
Jin et al., 2013). Blockade of interferon
gamma signaling has been reported to
be neuroprotective in experimental stroke
(Liesz et al., 2009, 2011; Seifert et al., 2014)
although other groups have reported alter-
native results in their model systems (Chu
et al., 2000; Lambertsen et al., 2004).
T cells are the main effector cell of this
neurodegenerative response and responsi-
ble for the release of the proinflammatory
interferon gamma, which is a potent acti-
vator of microglia becoming neurotoxic
(Boehm et al., 1997; Mebius and Kraal,
2005). Moreover, addition of interferon
gamma reverses the neuroprotection pro-
vided by splenectomy, demonstrating that
this cytokine plays a major role in the
spleen eliciting response resulting in fur-
ther neural death after stroke (Seifert et al.,
2012). As shown in this study, adminis-
tration of RTL directly inhibits the T cell
response to stroke, which concomitantly
deactivates the splenic response as well in
both young and old mice.
This treatment reduced infarct volumes
in both age groups by altering the immune
response to this neurological insult. Most
interestingly, the recombinant TCR lig-
and differentially affected components of
the immune response in the elderly and
young mice but still resulted in a blunted
immune response reducing neurodegener-
ation. This study illuminated differences in
the immune cell composition and inflam-
matory expression between these two age
groups in response to stroke. This is one of
the few studies that enlists elderly animals
which begins to provide insight into the
differences in the physiological responses
to stroke between young and the aged
animals. Such differences in young and
elderly could be responsible for the fail-
ure to translate findings at the bench to
those in the clinic since the vast major-
ity of studies use greatly cheaper young
ones. More studies using elderly rodents
will further supply additional insight in
translating stroke treatment from the pre-
clinical research to the clinical setting. This
study sets the basis for future ones to
develop new therapeutic approaches for a
treatment for stroke.
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